AI-Powered Synthetic Imaging Software to Further Redefine Speed and Quality of Accelerated MRI

The development of innovative solutions is not only redefining the landscape of artificial intelligence (AI)-based diagnostic imaging but also simplifying the ever-increasing complexity of workflows faced by technologists and radiologists. Now, new software available for clinical use in the US further redefines the speed and quality of accelerated MRI.

Subtle Medical (Menlo Park, CA, USA) has achieved FDA clearance for its innovative software solution, SubtleSYNTH. This software employs deep learning to create synthetic STIR images (SynthSTIRs) from already-acquired T1 and T2 weighted contrasts. Complementing Subtle's FDA-cleared SubtleMR software, which facilitates up to 60% faster image acquisition for MRI procedures on various scanner brands and models, SubtleSYNTH generates synthetic STIR images that require no additional acquisition time and are indistinguishable from traditionally obtained STIR images. This capability was recently validated for spinal imaging through a study with a diverse demographic.

Image: SubtleSYNTH creates synthetic STIR images with zero acquisition time that are interchangeable with conventionally acquired STIR images (Photo courtesy of Subtle Medical)

Clinically, the diagnostic quality of SubtleSYNTH matches that of conventional STIR images, confirming its state-of-the-art technology effectiveness. The integration of SubtleSYNTH into clinical settings enhances MRI exam efficiency, reducing the time patients spend in the scanner and elevating the standard of patient care. Initially focusing on spine imaging, Subtle Medical plans to extend SubtleSYNTH's application to include brain and musculoskeletal (MSK) imaging in future updates. By leveraging extensive data, Subtle Medical aims to continually improve the quality and speed of MRI imaging, pushing the boundaries of what is currently achievable in diagnostic imaging technology.

"We believe this software will offer substantial time savings for both new and existing scanners, reduce the need for rescans due to motion artifacts, and ease the workload on radiologists and technologists, ultimately improving patient care," said Ajit Shankaranarayanan, Chief Product Officer at Subtle Medical.

"With the attainment of FDA clearance, we mark a new era of MRI quality and efficiency. We will eagerly begin to deploy this valuable new tool to customers to help them realize maximum potential of improved quality and care," added Josh Gurewitz, Chief Commercial Officer at Subtle Medical.

Related Links:
Subtle Medical